

Summary of Utilization Management (UM) Program Changes

February 2022

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Jardiance and Farxiga (in SGLT-2 Inhibitors Step Therapy)</i>	dapagliflozin empagliflozin	Entresto (sacubitril/valsartan) has been added to the list of drugs that support the diagnosis of heart failure to allow the medications to be used in non-diabetic patients. This update is being added to the update from January.	Update	3/15/2022